The global urinalysis market is expected to reach USD 1.91 Billion by 2021 from USD 1.32 Billion in 2016, at a CAGR of 7.6%. The global market is broadly classified into product type, test type, applications, end user, and region.
On the basis of product type, consumables and instruments. The consumables segment is expected to account for the largest share of the global market in 2016. The high share of this segment is attributed to the wide use of disposables in urinalysis testing and research. This market is expected to witness high growth during the forecast period due to the introduction of new and advanced reagents & dipsticks and the utilization of disposables at a larger scale in the market.
Urinalysis market is segmented into biochemical urinalysis and sediment urinalysis on the basis of Test Type. The biochemical urinalysis segment is expected to drive the market during the forecast period. Technological advancement is a major factor driving market growth as it helps in introducing new and advanced automated biochemical urine analysers. For instance, in March 2015, Siemens launched the CLINITEK Novus Automated Urine Chemistry Analyser, which is based on dry pad urine chemistry technology as well as urinalysis strip cassette test format. Further, in April 2013, Biosense (India) developed uChek, a urine analyser that enables individuals to perform urinalysis via a smartphone. The uChek system works in conjugation with dipsticks for analyzing color changes in the dipstick and providing results.
The major end users of urinalysis systems include hospitals and clinics, research laboratories and institutes, diagnostic laboratories, and home care settings. The hospitals and clinical laboratories segment is expected to grow at a highest CAGR during forecast period. Increasing usage of dipsticks by hospitals and clinical laboratories for UTI and kidney diseases is the major factors driving the growth of this market.
Based on applications, the global urinalysis market is segmented into disease diagnostics and pregnancy tests. The disease diagnosis application segment is projected to witness the highest CAGR during the forecast period due to factors such as increasing research for the development of new urinalysis tests for better, early diagnosis of chronic diseases and increasing incidences of chronic diseases. The World Health Organization (WHO) predicts that by 2020, chronic diseases will account for about three-fourths of all deaths across the globe. As urinalysis plays an integral role in the diagnosis of such diseases, the urinalysis market is expected to grow significantly in the near future.
Geographically, the urinalysis market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the rising prevalence of kidney diseases and urinary tract infections in North American countries. The prevalence of diabetes is also on the rise; in the U.S., it is expected to reach 21% in 2050 from 14% in 2010 (Source: CDC).
The key players in the urinalysis market include Beckman Coulter (U.S.), Roche Diagnostics (Switzerland), Siemens AG (Germany), Sysmex (Japan) and Arkray, Inc. (Japan).